Solve FSHD and Modalis Therapeutics Corp. have established a strategic collaboration to develop an innovative therapy for facioscapulohumeral muscular dystrophy (FSHD).
Archeus Technologies Inc. and the Wisconsin Alumni Research Foundation (WARF) have entered into a strategic collaboration to advance ART-101, a next-generation prostate-specific membrane antigen (PSMA)-targeting small molecule, into clinical development for prostate cancer.
Orionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue therapies for treating cancer. Privately held Orionis is getting $105 million up front and could earn more than $2 billion in R&D, development, commercial and net sales milestones, plus royalties. The multiyear collaboration calls for Orionis to handle discovery and optimization of molecular glues, with Genentech in charge of later-stage preclinical and clinical development, regulatory filing and commercialization of any small molecules the partnership produces.
Quralis Corp. has entered into a number of agreements with the aim of advancing the treatment of fragile X syndrome, a genetic condition caused by a mutation of a single gene – fragile X messenger ribonucleoprotein 1 (FMR1) – on the X chromosome.
Genprex Inc. and University of Pittsburgh have entered into a new sponsored research agreement (SRA) to study GPX-002, Genprex’s gene therapy for diabetes in animal models of type 1 and type 2 diabetes.
Viverita Therapeutics Inc. has established a strategic research collaboration with Boehringer Ingelheim Pharma GmbH & Co. KG aimed at accelerating the discovery and validation of novel therapeutic targets for cancer.
Odylia Therapeutics Inc. has announced it is working under a codevelopment partnership with the NPHP1 Family Foundation to create an AAV-based gene replacement therapy for retinal dystrophy caused by mutations in the NPHP1 (nephrocystin-1) gene.
Creyon Bio Inc. has entered into a global licensing and multitarget research collaboration with Eli Lilly & Co. focused on the discovery, development and commercialization of novel RNA-targeted oligonucleotide therapies for a broad range of diseases.
Abtherx Inc. has signed a technology license agreement with Rondo Therapeutics with the aim of accelerating Rondo’s pipeline of bispecific antibodies. Rondo aims to advance the field of immuno-oncology, with a focus on treating solid tumors that fail to respond to current therapies.
Repertoire Immune Medicines Inc. has entered into a collaboration and license agreement with Genentech Inc., a member of the Roche Group, to discover and develop innovative T cell-targeted immune medicines to treat an autoimmune disease. Repertoire will use its Decode platform, which maps the immune synapse, to discover novel therapeutic targets.
RSS
